These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 27817957

  • 1. Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination.
    van Ravenhorst MB, Marinovic AB, van der Klis FR, van Rooijen DM, van Maurik M, Stoof SP, Sanders EA, Berbers GA.
    Vaccine; 2016 Dec 07; 34(50):6309-6315. PubMed ID: 27817957
    [Abstract] [Full Text] [Related]

  • 2. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
    van Ravenhorst MB, van der Klis FRM, van Rooijen DM, Knol MJ, Stoof SP, Sanders EAM, Berbers GAM.
    Vaccine; 2017 Aug 24; 35(36):4745-4752. PubMed ID: 28668575
    [Abstract] [Full Text] [Related]

  • 3. Salivary antibody levels in adolescents in response to a meningococcal serogroup C conjugate booster vaccination nine years after priming: systemically induced local immunity and saliva as potential surveillance tool.
    Stoof SP, van der Klis FR, van Rooijen DM, Bogaert D, Trzciński K, Sanders EA, Berbers GA.
    Vaccine; 2015 Jul 31; 33(32):3933-9. PubMed ID: 26100925
    [Abstract] [Full Text] [Related]

  • 4. Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine.
    Tejedor JC, Merino JM, Moro M, Navarro ML, Espín J, Omeñaca F, García-Sicilia J, Moreno-Pérez D, Ruiz-Contreras J, Centeno F, Barrio F, Cabanillas L, Muro M, Esporrin C, De Torres MJ, Caubet M, Boutriau D, Miller JM, Mesaros N.
    Pediatr Infect Dis J; 2012 Oct 31; 31(10):1074-7. PubMed ID: 22828645
    [Abstract] [Full Text] [Related]

  • 5. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB, van der Klis FRM, van Rooijen DM, Sanders EAM, Berbers GAM.
    Vaccine; 2017 Aug 24; 35(36):4753-4760. PubMed ID: 28647167
    [Abstract] [Full Text] [Related]

  • 6. Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers.
    Stoof SP, van der Klis FR, van Rooijen DM, Knol MJ, Sanders EA, Berbers GA.
    PLoS One; 2014 Aug 24; 9(6):e100651. PubMed ID: 24963638
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine.
    van Ravenhorst MB, den Hartog G, van der Klis FRM, van Rooijen DM, Sanders EAM, Berbers GAM.
    PLoS One; 2018 Aug 24; 13(4):e0191261. PubMed ID: 29672552
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.
    Nolan T, Booy R, Marshall HS, Richmond P, Nissen M, Ziegler JB, Baine Y, Traskine M, Jastorff A, Van der Wielen M.
    Pediatr Infect Dis J; 2019 Jun 24; 38(6):643-650. PubMed ID: 31116180
    [Abstract] [Full Text] [Related]

  • 11. Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
    de Whalley PC, Snape MD, Kelly DF, Banner C, Lewis S, Diggle L, John TM, Yu LM, Omar O, Borkowski A, Pollard AJ.
    Pediatr Infect Dis J; 2011 Nov 24; 30(11):e203-8. PubMed ID: 21673612
    [Abstract] [Full Text] [Related]

  • 12. Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease.
    Souza AR, Maruyama CM, Sáfadi MA, Lopes MH, Azevedo RS, Findlow H, Bai X, Borrow R, Weckx LY.
    Vaccine; 2016 Aug 05; 34(36):4327-34. PubMed ID: 27395566
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
    Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM.
    Pediatr Infect Dis J; 2015 Dec 05; 34(12):e298-307. PubMed ID: 26780033
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old children.
    Vesikari T, Forsten A, Laudat F, Li P, Van Der Wielen M, Hezareh M, Perez JL, Webber C.
    Vaccine; 2020 May 08; 38(22):3902-3908. PubMed ID: 32284274
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine.
    de Voer RM, Mollema L, Schepp RM, de Greeff SC, van Gageldonk PG, de Melker HE, Sanders EA, Berbers GA, van der Klis FR.
    PLoS One; 2010 Aug 13; 5(8):e12144. PubMed ID: 20730091
    [Abstract] [Full Text] [Related]

  • 18. Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines.
    Tejedor JC, Brzostek J, Konior R, Grunert D, Kolhe D, Baine Y, Van Der Wielen M.
    Clin Vaccine Immunol; 2016 Jul 13; 23(7):555-63. PubMed ID: 27145999
    [Abstract] [Full Text] [Related]

  • 19. Use of saliva to monitor meningococcal vaccine responses: proposing a threshold in saliva as surrogate of protection.
    van Ravenhorst MB, van der Klis FRM, van Rooijen DM, Sanders EAM, Berbers GAM.
    BMC Med Res Methodol; 2019 Jan 05; 19(1):1. PubMed ID: 30611213
    [Abstract] [Full Text] [Related]

  • 20. Different Dynamics for IgG and IgA Memory B Cells in Adolescents following a Meningococcal Serogroup C Tetanus Toxoid Conjugate Booster Vaccination Nine Years after Priming: A Role for Priming Age?
    Stoof SP, Buisman AM, van Rooijen DM, Boonacker R, van der Klis FR, Sanders EA, Berbers GA.
    PLoS One; 2015 Jan 05; 10(10):e0138665. PubMed ID: 26458006
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.